Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iradimed (IRMD) Research & Development (2016 - 2026)

Iradimed has reported Research & Development over the past 14 years, most recently at $956000.0 for Q1 2026.

  • Quarterly Research & Development rose 53.21% to $956000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Mar 2026, up 25.49% year-over-year, with the annual reading at $3.0 million for FY2025, 5.05% up from the prior year.
  • Research & Development was $956000.0 for Q1 2026 at Iradimed, up from $799031.0 in the prior quarter.
  • Over five years, Research & Development peaked at $3.0 million in Q1 2023 and troughed at $452555.0 in Q3 2023.
  • The 5-year median for Research & Development is $662599.0 (2022), against an average of $829750.2.
  • Year-over-year, Research & Development skyrocketed 477.92% in 2023 and then tumbled 72.63% in 2024.
  • A 5-year view of Research & Development shows it stood at $604744.0 in 2022, then rose by 7.56% to $650435.0 in 2023, then decreased by 12.3% to $570404.0 in 2024, then soared by 40.08% to $799031.0 in 2025, then grew by 19.64% to $956000.0 in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Research & Development are $956000.0 (Q1 2026), $799031.0 (Q4 2025), and $674362.0 (Q3 2025).